Web Menu

Product Search

Language

Share

Cardiac Maker
Home / Products / Colloidal Gold Platform / Cardiac Maker / Myoglobin/CK-MB/Troponin I Combo Rapid Test
Colloidal Gold Platform Fluorescence Platform Veterinary Platform Molecular Platform
Myoglobin/CK-MB/Troponin I Combo Rapid Test

Myoglobin/CK-MB/Troponin I Combo Rapid Test

Myoglobin (MYO), Creatine Kinase MB (CK-MB) and cardiac Troponin I (cTnI) are proteins released into the bloodstream after cardiac injury. Myoglobin is a heme-protein normally found in skeletal and cardiac muscle with a molecular weight of 17.8 kDa.1 When muscle cells are damaged, Myoglobin is released into the blood rapidly due to its relatively small size.

Contact Us
Product Features

Fast results  

Easy visual interpretation

Simple operation, no equipment required

High accuracy

Product Specification

Principle

Chromatographic Immunoassay

Format

Cassette

Specimen

Whole Blood/Serum/Plasma

Certificate

CE

Reading Time

10minutes

Storage Temperature

2-30°C

Shelf Life

2 Years

Accuracy

98.1%

Sensitivity

99.9%

Specificity

97.7%
Feedback
Send
Zhejiang Wantaifu Biotechnology Co., Ltd.
Zhejiang Wantaifu Biotechnology Co., Ltd., established in 2022, is now located in Hangzhou Bay Life Science Park, Economic and Technological Development Zone, Xiaoshan District, Hangzhou. It is an integrated innovative enterprise.

we are China wholesale Myoglobin/CK-MB/Troponin I Combo Rapid Test manufacturers and OEM Myoglobin/CK-MB/Troponin I Combo Rapid Test factory. The production center has 100,000-level automatic production lines, which provide effective guarantee for the high precision and high efficiency of products, convenient for customers to do flexible customization, design and processing of precision consumables.

Who

we are

30 Million
Registered capital
130 +
Employees
2022
was founded in
100 Million
Total investment
Our Latest News and Exhibitions
What steps are taken to minimize false positives or false negatives in tropical disease rapid tests? Minimizing false positives and false negatives is critical for the reliability and effectiveness of tropical disease rapid tests. False results can le... 14-02-2025
How does the fluorescence immunoassay analyzer account for the effects of fluorescence quenching by hemoglobin or bilirubin in clinical samples? Fluorescence quenching by hemoglobin, bilirubin, or other interfering substances in clinical samples can lead to decreased signal intensity and affect... 08-02-2025
How can the use of Typhoid Antigen Rapid Tests contribute to reducing the spread of typhoid fever in high-risk populations? The use of Typhoid Antigen Rapid Tests (TARTs) can significantly contribute to reducing the spread of typhoid fever in high-risk populations through s... 01-02-2025
How can the widespread use of Typhoid Antigen Rapid Tests help reduce the burden of typhoid fever in endemic regions? The widespread use of Typhoid Antigen Rapid Tests (TARTs) can play a pivotal role in reducing the burden of typhoid fever in endemic regions through s... 25-01-2025
What are the potential limitations of the Leishmania IgG/IgM rapid test in terms of false positives or negatives? The Leishmania IgG/IgM rapid test is a valuable diagnostic tool for detecting leishmaniasis, but like any diagnostic test, it has potential limitation... 17-01-2025
How can the usability of Influenza A+B rapid tests be improved to ensure ease of use by healthcare providers? Improving the usability of Influenza A+B rapid tests for healthcare providers involves streamlining the design and workflow to enhance efficiency, acc... 10-01-2025
honor